We are live on ! Find out more
BIAF icon

bioAffinity Technologies
BIAF

14 hedge funds and large institutions have $497K invested in bioAffinity Technologies in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

27% more funds holding

Funds holding: 11 → 14 (+3)

0.03% less ownership

Funds ownership: 3.47% → 3.44% (-0.03%)

49% less capital invested

Capital invested by funds: $973K → $497K (-$476K)

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SBIA
Sheaff Brock Investment Advisors
Indiana
+$35.6K
2
TSS
Two Sigma Securities
New York
+$19.3K
3
Citadel Advisors
Citadel Advisors
Florida
+$17.5K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$16.3K
5
TRCT
Tower Research Capital (TRC)
New York
+$5.43K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$6.04K
2
XT
XTX Topco
Cayman Islands
-$604
3
CS
Clear Street
New York
-$208

BIAF Hedge Fund Activity: Q4 2024 in Review

14 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q4 2024, worth a combined $497K — down 49% from $973K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BIAF positions and 0 closed out — a net gain of 3 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Sheaff Brock Investment Advisors, adding an estimated $35.6K. The largest seller was Morgan Stanley, cutting an estimated $6.04K.

  • 14 institutional investors held bioAffinity Technologies (BIAF) as of Q4 2024, up from 11 in Q3 2024.
  • Funds reported $497K of bioAffinity Technologies stock for Q4 2024, down 49% quarter-over-quarter.
  • 3 funds opened new bioAffinity Technologies positions in Q4 2024 and 0 closed out, a net change of +3 holders.
  • The largest bioAffinity Technologies buyer in Q4 2024 was Sheaff Brock Investment Advisors, an estimated $35.6K added.
  • The largest bioAffinity Technologies seller in Q4 2024 was Morgan Stanley, an estimated $6.04K sold.

Based on aggregated 13F filings for Q4 2024.